HekaBio Enters Licensing and Commercialization Agreement with SalutarisMD

HekaBio K.K. is pleased to announce a Japan licensing and commercialization agreement with Salutaris Medical Devices, Inc. for BetaCurve, a minimally invasive device incorporating Strontium 90 (Sr90) for the controlled delivery of episcleral radiation for the treatment of Polypoidal Choroidal Vasculopathy (PCV), a subset of Neovascular Age-related Macular Degeneration (wet-AMD) with high incidence in Asia.


SalutarisMD Executive Chairman George Mimura remarked, “We are delighted to partner with HekaBio to develop our therapy for patients in Japan where PCV is highly prevalent. We believe our system can enable therapeutic benefit for patients who have not responded to conventional treatments. We are in the planning stage to initiate an FDA-approved global pivotal study that will involve both the US and Japan.”


HekaBio CEO Robert E. Claar commented, “This is our second major strategic program leveraging our experience in radiotherapy for the benefit of physicians and patients in Japan. PCV is a large and growing unmet medical need in Japan, and the BetaCurve system is an excellent match for our capabilities and experience. Our partnership with Salutaris will enable us to further our mission of delivering simple and direct solutions to patients with difficult-to-treat diseases.”


About Salutaris MD


SalutarisMD is a clinical-stage medical device company specializing in radiotherapy to treat chronic ophthalmic diseases.


For more information, visit http://salutarismd.com/


Contact: George Mimura info@salutarismd.com

TEL: +1 (520) 638-7518


About HekaBio K.K.


HekaBio is a clinical-stage bio venture with an initial focus on radiation and other therapies for oncology and fibrotic disease. HekaBio in-licenses leading global innovations and successfully accelerates regulatory and commercial access in Japan and Asia.


Contact: Mari Tanaka

info@hekabio.com

TEL: +81 (3) 6205-7585

最新記事

すべて表示

HekaBio Completes Financing Round

HekaBio K.K. announced today that it has successfully completed a financing round of JPY 400 million. Proceeds will be used to strengthen and expand HekaBio’s portfolio of innovations in development i